PT1039912E - Agentes angiostaticos e composicoes para tratar glaucoma glc1a - Google Patents
Agentes angiostaticos e composicoes para tratar glaucoma glc1aInfo
- Publication number
- PT1039912E PT1039912E PT98961956T PT98961956T PT1039912E PT 1039912 E PT1039912 E PT 1039912E PT 98961956 T PT98961956 T PT 98961956T PT 98961956 T PT98961956 T PT 98961956T PT 1039912 E PT1039912 E PT 1039912E
- Authority
- PT
- Portugal
- Prior art keywords
- angiostatic
- glc1a
- treating glaucoma
- composition agents
- agents
- Prior art date
Links
- 208000010412 Glaucoma Diseases 0.000 title abstract 2
- 101000585663 Homo sapiens Myocilin Proteins 0.000 title abstract 2
- 102100029839 Myocilin Human genes 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 230000000964 angiostatic effect Effects 0.000 title 1
- 239000004037 angiogenesis inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J11/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
- C07J41/0027—Azides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
- C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
- C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/994,114 US5990099A (en) | 1988-10-31 | 1997-12-19 | Angiostatic agents and methods and compositions for controlling ocular hypertension |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1039912E true PT1039912E (pt) | 2002-12-31 |
Family
ID=25540297
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT98961956T PT1039912E (pt) | 1997-12-19 | 1998-12-07 | Agentes angiostaticos e composicoes para tratar glaucoma glc1a |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US5990099A (pt) |
| EP (1) | EP1039912B1 (pt) |
| JP (1) | JP2001526233A (pt) |
| AT (1) | ATE221781T1 (pt) |
| AU (1) | AU734436B2 (pt) |
| BR (1) | BR9813684A (pt) |
| CA (1) | CA2315829C (pt) |
| DE (1) | DE69807115T2 (pt) |
| DK (1) | DK1039912T3 (pt) |
| ES (1) | ES2177112T3 (pt) |
| PT (1) | PT1039912E (pt) |
| WO (1) | WO1999032127A1 (pt) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001041781A2 (en) * | 1999-12-09 | 2001-06-14 | Alcon Universal Ltd. | Id protein inhibitors for treating ocular diseases |
| US9603741B2 (en) | 2000-05-19 | 2017-03-28 | Michael S. Berlin | Delivery system and method of use for the eye |
| US8679089B2 (en) | 2001-05-21 | 2014-03-25 | Michael S. Berlin | Glaucoma surgery methods and systems |
| ATE377404T1 (de) | 2000-05-19 | 2007-11-15 | Michael S Berlin | Laserapplikationssystem und methode zur verwendung im auge |
| US7402577B2 (en) * | 2001-10-03 | 2008-07-22 | Merck & Co., Inc. | Androstane 17-beta-carboxamides as androgen receptor modulators |
| GB0316290D0 (en) | 2003-07-11 | 2003-08-13 | Glaxo Group Ltd | Novel compounds |
| EP1841780B1 (en) | 2005-01-10 | 2011-07-27 | Glaxo Group Limited | Androstane 17-alpha-carbonate derivatives for use in the treatment of allergic and inflammatory conditions |
| DE202006021081U1 (de) * | 2005-07-12 | 2012-05-08 | Dmi Biosciences, Inc. | Produkte zur Behandlung von Krankheiten |
| US8968396B2 (en) | 2007-07-23 | 2015-03-03 | Powervision, Inc. | Intraocular lens delivery systems and methods of use |
| US20170360609A9 (en) | 2007-09-24 | 2017-12-21 | Ivantis, Inc. | Methods and devices for increasing aqueous humor outflow |
| EP2259833A1 (en) | 2008-03-05 | 2010-12-15 | Ivantis, INC. | Methods and apparatus for treating glaucoma |
| HUE027463T2 (en) | 2008-05-28 | 2016-09-28 | Reveragen Biopharma Inc | Non-hormonal steroid modulators of nf-kb for treatment of disease |
| DK2326332T3 (da) * | 2009-06-22 | 2013-03-04 | Dmi Acquistion Corp | Fremgangsmåde til behandling af sygdomme |
| SG177302A1 (en) * | 2009-06-22 | 2012-02-28 | Dmi Acquisition Corp | Methods and products for treatment of diseases |
| AU2010271218B2 (en) | 2009-07-09 | 2017-02-02 | Alcon Inc. | Ocular implants and methods for delivering ocular implants into the eye |
| WO2011006078A1 (en) | 2009-07-09 | 2011-01-13 | Ivantis, Inc. | Single operator device for delivering an ocular implant |
| US9198921B2 (en) | 2010-04-05 | 2015-12-01 | Reveragen Biopharma, Inc. | Non-hormonal steroid modulators of NF-κB for treatment of disease |
| US20120283557A1 (en) | 2011-05-05 | 2012-11-08 | Berlin Michael S | Methods and Apparatuses for the Treatment of Glaucoma using visible and infrared ultrashort laser pulses |
| US8657776B2 (en) | 2011-06-14 | 2014-02-25 | Ivantis, Inc. | Ocular implants for delivery into the eye |
| US8663150B2 (en) | 2011-12-19 | 2014-03-04 | Ivantis, Inc. | Delivering ocular implants into the eye |
| US9358156B2 (en) | 2012-04-18 | 2016-06-07 | Invantis, Inc. | Ocular implants for delivery into an anterior chamber of the eye |
| US10617558B2 (en) | 2012-11-28 | 2020-04-14 | Ivantis, Inc. | Apparatus for delivering ocular implants into an anterior chamber of the eye |
| CN104968350A (zh) | 2012-12-19 | 2015-10-07 | 安皮奥制药股份有限公司 | 疾病的治疗方法 |
| EP3785668A1 (en) | 2013-03-15 | 2021-03-03 | Alcon Inc. | Intraocular lens storage and loading devices and methods of use |
| US10709547B2 (en) | 2014-07-14 | 2020-07-14 | Ivantis, Inc. | Ocular implant delivery system and method |
| EP3006453A1 (en) | 2014-10-08 | 2016-04-13 | Cosmo Technologies Ltd. | 17alpha-monoesters and 17alpha,21-diesters of cortexolone for use in the treatment of tumors |
| US10799514B2 (en) | 2015-06-29 | 2020-10-13 | Reveragen Biopharma, Inc. | Non-hormonal steroid modulators of NF-kappa beta for treatment of disease |
| JP6837475B2 (ja) | 2015-08-14 | 2021-03-03 | イバンティス インコーポレイテッド | 圧力センサを備えた眼用インプラントおよび送達システム |
| US11938058B2 (en) | 2015-12-15 | 2024-03-26 | Alcon Inc. | Ocular implant and delivery system |
| EP4371535A3 (en) | 2018-02-22 | 2024-08-14 | Alcon Inc. | Ocular implant |
| US11382922B2 (en) | 2019-03-07 | 2022-07-12 | Reveragen Biopharma, Inc. | Aqueous oral pharmaceutical suspension compositions |
| AU2022205382B2 (en) | 2021-01-11 | 2026-02-19 | Alcon Inc. | Systems and methods for viscoelastic delivery |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4642355A (en) * | 1984-02-24 | 1987-02-10 | Otsuka Pharmaceutical Factory, Inc. | Proline derivatives |
| US4863912A (en) * | 1986-05-19 | 1989-09-05 | New York Medical College | Use of tetrahydrocortisol in glaucoma therapy |
| US4876250A (en) * | 1988-10-31 | 1989-10-24 | Alcon Laboratories, Inc. | Methods for controlling ocular hypertension with angiostatic steroids |
| US5371078A (en) * | 1988-10-31 | 1994-12-06 | Alcon Laboratories, Inc. | Angiostatic steroids and methods and compositions for controlling ocular hypertension |
| AU657690B2 (en) * | 1990-06-11 | 1995-03-23 | Alcon Laboratories, Inc. | Steroids which inhibit angiogenesis |
| DK0614463T3 (da) * | 1991-11-22 | 2003-03-31 | Alcon Lab Inc | Angiostatiske steroider |
| US5646136A (en) * | 1994-01-04 | 1997-07-08 | Duke University | Methods of inhibiting angiogenesis and tumor growth, and treating ophthalmologic conditions with angiostatic and therapeutic steroids |
| US5606043A (en) * | 1994-11-03 | 1997-02-25 | The Regents Of The University Of California | Methods for the diagnosis of glaucoma |
-
1997
- 1997-12-19 US US08/994,114 patent/US5990099A/en not_active Expired - Fee Related
-
1998
- 1998-12-07 AT AT98961956T patent/ATE221781T1/de active
- 1998-12-07 JP JP2000525118A patent/JP2001526233A/ja active Pending
- 1998-12-07 BR BR9813684-4A patent/BR9813684A/pt not_active Application Discontinuation
- 1998-12-07 DK DK98961956T patent/DK1039912T3/da active
- 1998-12-07 CA CA002315829A patent/CA2315829C/en not_active Expired - Fee Related
- 1998-12-07 EP EP98961956A patent/EP1039912B1/en not_active Expired - Lifetime
- 1998-12-07 WO PCT/US1998/025913 patent/WO1999032127A1/en not_active Ceased
- 1998-12-07 ES ES98961956T patent/ES2177112T3/es not_active Expired - Lifetime
- 1998-12-07 DE DE69807115T patent/DE69807115T2/de not_active Expired - Lifetime
- 1998-12-07 AU AU17142/99A patent/AU734436B2/en not_active Ceased
- 1998-12-07 PT PT98961956T patent/PT1039912E/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2001526233A (ja) | 2001-12-18 |
| CA2315829C (en) | 2009-05-12 |
| EP1039912B1 (en) | 2002-08-07 |
| DE69807115D1 (de) | 2002-09-12 |
| ES2177112T3 (es) | 2002-12-01 |
| BR9813684A (pt) | 2000-10-10 |
| AU734436B2 (en) | 2001-06-14 |
| DK1039912T3 (da) | 2002-10-28 |
| EP1039912A1 (en) | 2000-10-04 |
| HK1029922A1 (en) | 2001-04-20 |
| AU1714299A (en) | 1999-07-12 |
| US5990099A (en) | 1999-11-23 |
| CA2315829A1 (en) | 1999-07-01 |
| ATE221781T1 (de) | 2002-08-15 |
| WO1999032127A1 (en) | 1999-07-01 |
| DE69807115T2 (de) | 2002-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2177112T3 (es) | Agentes angiostaticos y composiciones para tratar el glaucoma glc1a. | |
| ES2191152T3 (es) | Terapia combinada para el tratamiento de psicosis. | |
| ID29393A (id) | Komposisi pengobatan kanker dan metoda penggunaan minyak-minyak esensil tanaman alamiah | |
| ES2186015T3 (es) | Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol. | |
| BR9813767A (pt) | Processo e composição para tratar glaucoma de glc1a | |
| ES2133807T3 (es) | Compuestos de peptidilo y su uso terapeutico como inhibidores de metaloproteasas. | |
| PT935465E (pt) | Compostos novos de imidazole substituido | |
| PT1093819E (pt) | Compostos e composicoes para fornecimento de agentes activos | |
| PT971713E (pt) | Utilizacao de inibidores da colinesterase para tratamento de desordens da atencao | |
| BR0112160A (pt) | Agentes antiinflamatórios seletivos para glicocorticóides | |
| BR9913800A (pt) | Método para tratar glaucoma, e, composição para tratar glaucoma | |
| ES2184077T3 (es) | Nuevas fenantridinas sustituidas en la posicion 6. | |
| DK0682664T3 (da) | Forbindelser med både potent calciumantagonist og antioxiderende aktivitet og anvendelse deraf som cytobeskyttende midler | |
| TR200000927T2 (tr) | Prostaglandin agonistleri ve kemik bozukluklarının tedavisi | |
| DE69703294D1 (de) | Zusammensetzungen die konjugate von cis-docosahexaenoic-säure und taxotere enthalten | |
| CY1108610T1 (el) | Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες | |
| IS2241B (is) | Píperasín afleiður og notkun þeirra sem bólgueyðandi miðlar | |
| AR023777A1 (es) | Nuevos compuestos | |
| BR0316203A (pt) | Uso de um agente antialérgico e um esteróide para tratar rinite alérgica | |
| DK0842934T3 (da) | 5-HT1F agonister | |
| PT902789E (pt) | Derivados de androsteno | |
| BR9912327A (pt) | Inibidores da uroquinase | |
| BR9813797A (pt) | Processo para tratar glaucoma de glc1a, e, composição para controlar glaucoma de glc1a. | |
| DK0988040T3 (da) | Anvendelse af glucosamin og glucasamin-derivater til hurtig lindring af klöe eller lokaliseret smerte | |
| BR9809848A (pt) | Composição |